Amytrx Therapeutics
PrivateLast Round
Series A
May 25, 2022
Total Funding Raised
$18M
Company Overview
Amytrx Therapeutics is a biopharmaceutical company that develops anti-inflammatory peptide therapies for the treatment of chronic inflammatory and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amytrx Therapeutics Comparables
Compare Amytrx Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Carocell Bio | 76% | |
| Novacell Technology | 76% | |
| PEP-Therapy | 62% | |
Amytrx Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 25, 2022 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2024
Monthly visitors grew 419% MoM, from 270 to 1.4K.
- May 25, 2022
$18M round completed.
Amytrx Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Amytrx Therapeutics's valuation, stock price, and market status.